Expression of Syndecan-1 and Cyclin D1 in Salivary Gland Tumors in Relation to Clinicopathological Parameters

References

• Zhu S, Schuerch C, Hunt J. Review and updates of immunohistochemistry in selected salivary gland and head and neck tumors. Arch Pathol Lab Med. 2015;139:55–66. doi:10.5858/arpa.2014-0167-RA
   PubMed Web of Science ®Google Scholar
• Sowa P, Goroszkiewicz K, Szydelko J, et al. A review of selected factors of salivary gland tumour formation and malignant transformation. Biomed Res Int. 2018;2018. doi:10.1155/2018/2897827
   Web of Science ®Google Scholar
• Speight PM, Barrett AW. Salivary gland tumours: diagnostic challenges and an update on the latest WHO classification. Diagnostic Histopathol. 2020;26:147–158. doi:10.1016/j.mpdhp.2020.01.001
   Google Scholar
• Skálová A, Hyrcza MD, Leivo I. Update from the 5th edition of the World Health Organization classification of head and neck tumors: salivary glands. Head Neck Pathol. 2022;16:40–53. doi:10.1007/s12105-022-01420-1
   PubMed Web of Science ®Google Scholar
• Valstar MH, de Ridder M, van den Broek EC, et al. Salivary gland pleomorphic adenoma in the Netherlands: a nationwide observational study of primary tumor incidence, malignant transformation, recurrence, and risk factors for recurrence. Oral Oncol. 2017;66:93–99. doi:10.1016/j.oraloncology.2017.01.004
   PubMed Web of Science ®Google Scholar
• Alhindi N, Sindi A, Binmadi N, Elias W. A retrospective study of oral and maxillofacial pathology lesions diagnosed at the Faculty of Dentistry, King Abdulaziz University. Clin Cosmet Investig Dent. 2019;11:45–52. doi:10.2147/CCIDE.S190092
   PubMed Web of Science ®Google Scholar
• Salim G, Mohammed D, Garib B. Prevalence of oral maxillofacial lesions in major histopathological centers in Sulaimani City. Sulaimani Dent J. 2021;8:1–9. doi:10.17656/sdj.10134
   Google Scholar
• Ali AA, Suresh CS, Al-Tamimi D, et al. A survey of oral and maxillofacial biopsies in the Eastern Province of Saudi Arabia: a 10 years’ retrospective study. J Oral Maxillofac Surg Med Pathol. 2013;25:393–398. doi:10.1016/j.ajoms.2012.12.003
   Google Scholar
• Fuoad SAA, Mohammad DN, Hamied MAS, Garib BT. Oro-facial malignancy in north of Iraq: a retrospective study of biopsied cases. BMC Oral Health. 2021;21. doi:10.1186/s12903-021-01521-3
   PubMed Web of Science ®Google Scholar
• Szatmári T, Ötvös R, Hjerpe A, Dobra K. Syndecan-1 in cancer: implications for cell signaling, differentiation, and prognostication. Dis Markers. 2015;2015:1–13. doi:10.1155/2015/796052
   Web of Science ®Google Scholar
• Couchman JR. Syndecan-1 (Cd138), carcinomas and emt. Int J Mol Sci. 2021;22(8):4227. doi:10.3390/ijms22084227
   PubMed Web of Science ®Google Scholar
• Alaeddini M, Yazdani F, Etemad-Moghadam S. Stromal and epithelial syndecan-1 expression in benign and malignant salivary gland tumors: which is more reflective of behavior? Braz J Otorhinolaryngol. 2021;87:171–177. doi:10.1016/j.bjorl.2019.07.006
   PubMed Web of Science ®Google Scholar
• Montalto FI, De Amicis F. Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma. Cells. 2020;9(12):2648. doi:10.3390/cells9122648
   PubMed Web of Science ®Google Scholar
• Tenório JDR., da SilvaL P, Xavier MGDA., Santana T, Do Nascimento GJF, Sobral APV. Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors. Eur Arch Oto Rhino Laryngol. 2018;275:2341–2347. doi:10.1007/s00405-018-5058-5
   PubMed Web of Science ®Google Scholar
• Jour G, West K, Ghali V, Shank D, Ephrem G, Wenig BM. Differential expression of p16INK4A and cyclin D1 in benign and malignant salivary gland tumors: a study of 44 cases. Head Neck Pathol. 2013;7:224–231. doi:10.1007/s12105-012-0417-9
   PubMedGoogle Scholar
• Moghadam SA, Jahani N, Mokhtari S. Immunohistochemical analysis of cyclind1 expression in salivary gland tumors. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119:e174. doi:10.1016/j.oooo.2014.07.320
   Google Scholar
• Meyer MT, Watermann C, Dreyer T, Ergün S, Karnati S. 2021 update on diagnostic markers and translocation in salivary gland tumors. Int J Mol Sci. 2021;22(13):6771. doi:10.3390/ijms22136771
   PubMed Web of Science ®Google Scholar
• Yazici D, Guney Z, Coktu MY, Yildirim I, Arikan OK. Clinicopathological analysis of parotid masses: six-year experience of a tertiary center. J Pak Med Assoc. 2020;70:308–312.
   PubMed Web of Science ®Google Scholar
• Albsoul NM, Mismar A, Obeidat F. Parotid tumors in Jordan: a demographic and clinicopathological analysis parotid tumors in Jordan: a demographic and clinicopathological analysis. Revista Kasmera. 2015;2015:1–12.
   Google Scholar
• Ashkavandi Z, Ashraf MJ, Afandak N. A clinicopathologic study of 82 Intraoral Minor Salivary Gland Tum. Iran Red Crescent Med J. 2011;13:563–565.
   Web of Science ®Google Scholar
• Al-Khiro FI. Salivary gland tumors: a review of 171 cases, with particular reference to histological types, site, age and gender distribution. J Baghdad Coll Dent. 2014;26:88–91. doi:10.12816/0015170
   Google Scholar
• Alsanie I, Rajab S, Cottom H, et al. Distribution and frequency of salivary gland tumours: an international multicenter study. Head Neck Pathol. 2022;16:1043–1054.
   PubMed Web of Science ®Google Scholar
• Ribeiro A, de Carvalho ALSH, Koth VS, Campos MM. Tumores de Glândulas Salivares: análise Retrospectiva de Dez Anos em um Hospital Escola Brasileiro. Rev Bras Cancerol. 2021;67. doi:10.32635/2176-9745.RBC.2021v67n4.1452
   Google Scholar
• Strizova Z, Kuchar M, Capkova L, et al. Fas-fas ligand interplay in the periphery of salivary gland carcinomas as a new checkpoint predictor for disease severity and immunotherapy response. Biomedicines. 2021;9:402.
   PubMed Web of Science ®Google Scholar
• Lai X, Li Q, Wu F, et al. Epithelial-mesenchymal transition and metabolic switching in cancer: lessons from somatic cell reprogramming. Front Cell Dev Biol. 2020;8:760.
   PubMed Web of Science ®Google Scholar
• Szatmári T, Dobra K. The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors. Front Oncol. 2013;3:310.
   PubMedGoogle Scholar
• Kind S, Merenkow C, Büscheck F, et al. Prevalence of syndecan-1 (CD138) expression in different kinds of human tumors and normal tissues. Dis Markers. 2019;2019:1–11. doi:10.1155/2019/4928315
   Web of Science ®Google Scholar
• Gallimidi AB, Nussbaum G, Hermano E, et al. Syndecan-1 deficiency promotes tumor growth in a murine model of colitis-induced colon carcinoma. PLoS One. 2017;12:e0174343. doi:10.1371/journal.pone.0174343
   PubMed Web of Science ®Google Scholar
• Shimada K, Anai S, Fujii T, Tanaka N, Fujimoto K, Konishi N. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells. J Pathol. 2013;231:495–504. doi:10.1002/path.4271
   PubMed Web of Science ®Google Scholar
• Patel RS, Rose B, Bawdon H, et al. Cyclin D1 and p16 expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland. Histopathology. 2007;51:691–696. doi:10.1111/j.1365-2559.2007.02853.x
   PubMed Web of Science ®Google Scholar
• Moharil RB, Khandekar S, Dive A, Bodhade A. Cyclin D1 in oral premalignant lesions and oral squamous cell carcinoma: an immunohistochemical study. J Oral Maxillofac Pathol. 2020;24(2):397. doi:10.4103/jomfp.JOMFP_164_20
   PubMedGoogle Scholar
• Al-Azzawi LM, Ghazi OM, Hussein WAL. Immunohistochemical expression of cyclin D1 in mucoepidermoid and adenoid cystic carcinoma of the salivary glands. J Baghdad Coll Dent. 2015;27:64–69. doi:10.12816/0015037
   Google Scholar